A marketing lead at a large global biotech company has expertise in pregnancy conditions and molecular diagnostics, but also discusses infertility and chronic conditions (e.g., endometriosis, PCOS). They primarily see precision medicine in this space through a molecular diagnostic lens but acknowledge that digital health tools could be used to potentially screen patients in the future. Research and investment are considered key challenges, including a lack of sample availability tied to clinical and various “omic” data in women’s health and a lack of NIH funding. This stakeholder believes these are upstream bottlenecks causing other challenges in this space, such as (non-invasive) diagnostics and treatments. Unmet needs are considered highest in endometriosis, perinatal conditions, and menopause, and next highest in PCOS, pregnancy complications, and contraceptives. They believe endometriosis and artificial conception will see the highest precision medicine activity in the next 1-2 years. This stakeholder is excited by activity from Mirvie, Hera Biotech, NextGen Jane, Adyn, and Dama Health. A winning solution for this stakeholder is a differential diagnostic panel for pelvic pain.

Campaign Details

Precision Medicine Opportunities in Women’s Health Ad Board

DeciBio conducted 11 interviews with OB/GYNs and KOLs in biotech / VC / pharma to explore key unmet needs / challenges, opportunities for precision medicine, and emerging players in women’s health.